Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells.

Graham MK, Kim J, Da J, Brosnan-Cashman JA, Rizzo A, Baena Del Valle JA, Chia L, Rubenstein M, Davis C, Zheng Q, Cope L, Considine M, Haffner MC, De Marzo AM, Meeker AK, Heaphy CM.

Mol Cancer Res. 2019 Oct 14. doi: 10.1158/1541-7786.MCR-19-0654. [Epub ahead of print]

PMID:
31611308
2.

Interleukin-8 Expression is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer.

Maynard JP, Ertunc O, Kulac I, Baena Del Valle JA, De Marzo AM, Sfanos KS.

Mol Cancer Res. 2019 Oct 11. pii: molcanres.0595.2019. doi: 10.1158/1541-7786.MCR-19-0595. [Epub ahead of print]

PMID:
31604846
3.

Histopathological Terminology Standards for the Reporting of Prostatic Epithelial Lesions in Dogs.

Palmieri C, Foster RA, Grieco V, Fonseca-Alves CE, Wood GA, Culp WTN, Murua Escobar H, De Marzo AM, Laufer-Amorim R.

J Comp Pathol. 2019 Aug;171:30-37. doi: 10.1016/j.jcpa.2019.07.005. Epub 2019 Aug 6. Review.

PMID:
31540623
4.

A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer.

Zhang Y, Zhou CK, Rencsok EM, Fall K, Lotan TL, Loda M, Giunchi F, Platz EA, De Marzo AM, Mucci LA, Fiorentino M, Ebot EM.

Cancer Epidemiol Biomarkers Prev. 2019 Sep 18. doi: 10.1158/1055-9965.EPI-19-0713. [Epub ahead of print]

PMID:
31533941
5.

Effective targeting of RNA polymerase I in treatment-resistant prostate cancer.

Low JY, Sirajuddin P, Moubarek M, Agarwal S, Rege A, Guner G, Liu H, Yang Z, De Marzo AM, Bieberich C, Laiho M.

Prostate. 2019 Dec;79(16):1837-1851. doi: 10.1002/pros.23909. Epub 2019 Sep 16.

PMID:
31524299
6.

Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis.

Porter CM, Haffner MC, Kulac I, Maynard JP, Baena-Del Valle JA, Isaacs WB, Yegnasubramanian S, De Marzo AM, Sfanos KS.

Am J Pathol. 2019 Nov;189(11):2311-2322. doi: 10.1016/j.ajpath.2019.07.016. Epub 2019 Sep 6.

PMID:
31499027
7.

Trichomonas vaginalis infection and prostate-specific antigen concentration: Insights into prostate involvement and prostate disease risk.

Langston ME, Bhalla A, Alderete JF, Nevin RL, Pakpahan R, Hansen J, Elliott D, De Marzo AM, Gaydos CA, Isaacs WB, Nelson WG, Sokoll LJ, Zenilman JM, Platz EA, Sutcliffe S.

Prostate. 2019 Oct;79(14):1622-1628. doi: 10.1002/pros.23886. Epub 2019 Aug 2.

PMID:
31376187
8.

Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease.

Zarif JC, Baena-Del Valle JA, Hicks JL, Heaphy CM, Vidal I, Luo J, Lotan TL, Hooper JE, Isaacs WB, Pienta KJ, De Marzo AM.

Eur Urol Oncol. 2019 Jul;2(4):429-436. doi: 10.1016/j.euo.2018.09.014. Epub 2018 Oct 19.

PMID:
31277779
9.

Serum Urate, Genetic Variation, and Prostate Cancer Risk: Atherosclerosis Risk in Communities (ARIC) Study.

Wang A, Barber JR, Tin A, De Marzo AM, Kottgen A, Joshu CE, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1259-1261. doi: 10.1158/1055-9965.EPI-19-0161.

PMID:
31263056
10.

Inflammation-associated pathologies in a case of prostate schistosomiasis: Implications for a causal role in prostate carcinogenesis.

Peiffer LB, Poynton SL, Ernst SE, Hicks JL, De Marzo AM, Sfanos KS.

Prostate. 2019 Aug;79(11):1316-1325. doi: 10.1002/pros.23841. Epub 2019 Jun 18.

PMID:
31212384
11.

Cancer overdiagnosis: a biological challenge and clinical dilemma.

Srivastava S, Koay EJ, Borowsky AD, De Marzo AM, Ghosh S, Wagner PD, Kramer BS.

Nat Rev Cancer. 2019 Jun;19(6):349-358. doi: 10.1038/s41568-019-0142-8. Review.

PMID:
31024081
12.

Quantitative proteomic analysis of a genetically induced prostate inflammation mouse model via custom 4-plex DiLeu isobaric labeling.

Hao L, Thomas S, Greer T, Vezina CM, Bajpai S, Ashok A, De Marzo AM, Bieberich CJ, Li L, Ricke WA.

Am J Physiol Renal Physiol. 2019 Jun 1;316(6):F1236-F1243. doi: 10.1152/ajprenal.00387.2018. Epub 2019 Apr 17.

PMID:
30995113
13.

Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.

Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, Epstein JI, Pritchard CC, Lotan TL.

J Pathol. 2019 Sep;249(1):79-89. doi: 10.1002/path.5283. Epub 2019 May 24.

PMID:
30993692
14.

Consequences of interleukin 1β-triggered chronic inflammation in the mouse prostate gland: Altered architecture associated with prolonged CD4+ infiltration mimics human proliferative inflammatory atrophy.

Ashok A, Keener R, Rubenstein M, Stookey S, Bajpai S, Hicks J, Alme AK, Drake CG, Zheng Q, Trabzonlu L, Yegnasubramanian S, De Marzo AM, Bieberich CJ.

Prostate. 2019 May;79(7):732-745. doi: 10.1002/pros.23784. Epub 2019 Mar 22.

PMID:
30900284
15.

TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer.

Kaur HB, Lu J, Guedes LB, Maldonado L, Reitz L, Barber JR, De Marzo AM, Tomlins SA, Sfanos KS, Eisenberger M, Schaeffer EM, Joshu CE, Lotan TL.

Hum Pathol. 2019 May;87:95-102. doi: 10.1016/j.humpath.2019.02.006. Epub 2019 Mar 6.

PMID:
30851334
16.

If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease.

Sfanos KS, Yegnasubramanian S, Nelson WG, Lotan TL, Kulac I, Hicks JL, Zheng Q, Bieberich CJ, Haffner MC, De Marzo AM.

Asian J Urol. 2019 Jan;6(1):10-25. doi: 10.1016/j.ajur.2018.11.006. Epub 2018 Dec 12. Review.

17.

Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis.

Marrone MT, Joshu CE, Peskoe SB, De Marzo AM, Heaphy CM, Lupold SE, Meeker AK, Platz EA.

Clin Chem. 2019 Jan;65(1):189-198. doi: 10.1373/clinchem.2018.293365. Epub 2018 Dec 5.

PMID:
30518666
18.

A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growth.

Yu SH, Maynard JP, Vaghasia AM, De Marzo AM, Drake CG, Sfanos KS.

Prostate. 2019 Feb;79(2):215-222. doi: 10.1002/pros.23726. Epub 2018 Oct 21.

PMID:
30345534
19.

Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer.

Guedes LB, Morais CL, Fedor H, Hicks J, Gurel B, Melamed J, Lee P, Gopalan A, Knudsen BS, True LD, Scher HI, Fine SW, Trock BJ, De Marzo AM, Lotan TL.

Arch Pathol Lab Med. 2019 Mar;143(3):338-348. doi: 10.5858/arpa.2018-0068-OA. Epub 2018 Oct 8.

PMID:
30295067
20.

PTEN status assessment in the Johns Hopkins active surveillance cohort.

Tosoian JJ, Guedes LB, Morais CL, Mamawala M, Ross AE, De Marzo AM, Trock BJ, Han M, Carter HB, Lotan TL.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):176-181. doi: 10.1038/s41391-018-0093-2. Epub 2018 Oct 2.

21.

CD38 is methylated in prostate cancer and regulates extracellular NAD.

Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, Sboner A, Bareja R, Esopi D, Isaacs WB, Yegnasubramanian S, Rettig MB, Elashoff DA, Platz EA, De Marzo AM, Teitell MA, Goldstein AS.

Cancer Metab. 2018 Sep 21;6:13. doi: 10.1186/s40170-018-0186-3. eCollection 2018.

22.

Redox-Responsive Nanoparticle-Mediated Systemic RNAi for Effective Cancer Therapy.

Xu X, Wu J, Liu S, Saw PE, Tao W, Li Y, Krygsman L, Yegnasubramanian S, De Marzo AM, Shi J, Bieberich CJ, Farokhzad OC.

Small. 2018 Oct;14(41):e1802565. doi: 10.1002/smll.201802565. Epub 2018 Sep 17.

23.

Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors.

Haffner MC, Taheri D, Luidy-Imada E, Palsgrove DN, Eich ML, Netto GJ, Matoso A, Nirschl TR, Zheng Q, Hicks JL, Nelson WG, De Marzo AM, Marchionni L, Drake CG, Yegnasubramanian S.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8580-E8582. doi: 10.1073/pnas.1803292115. Epub 2018 Sep 4. No abstract available.

24.

Malignant Peripheral Nerve Sheath Tumors Show Decreased Global DNA Methylation.

Nix JS, Haffner MC, Ahsan S, Hicks J, De Marzo AM, Blakeley J, Raabe EH, Rodriguez FJ.

J Neuropathol Exp Neurol. 2018 Oct 1;77(10):958-963. doi: 10.1093/jnen/nly076.

PMID:
30169729
25.

Sustained influence of infections on prostate-specific antigen concentration: An analysis of changes over 10 years of follow-up.

Langston ME, Pakpahan R, Nevin RL, De Marzo AM, Elliott DJ, Gaydos CA, Isaacs WB, Nelson WG, Sokoll LJ, Zenilman JM, Platz EA, Sutcliffe S.

Prostate. 2018 Sep;78(13):1024-1034. doi: 10.1002/pros.23660. Epub 2018 May 30.

26.

Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer.

Kang H, Antonarakis ES, Luo J, Zheng Q, Rooper L, De Marzo AM, Westra WH, Lotan TL.

Oral Oncol. 2018 Sep;84:134-136. doi: 10.1016/j.oraloncology.2018.06.026. Epub 2018 Jun 28. No abstract available.

PMID:
30122219
27.

Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities.

Trabzonlu L, Kulac I, Zheng Q, Hicks JL, Haffner MC, Nelson WG, Sfanos KS, Ertunc O, Lotan TL, Heaphy CM, Meeker AK, Yegnasubramanian S, De Marzo AM.

Cold Spring Harb Perspect Med. 2019 Apr 1;9(4). pii: a030403. doi: 10.1101/cshperspect.a030403. Review.

PMID:
30082453
28.

Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors.

DuPre NC, Flavin R, Sfanos KS, Unger RH, To S, Gazeeva E, Fiorentino M, De Marzo AM, Rider JR, Mucci LA; Transdisciplinary Prostate Cancer Partnership(ToPCaP).

Prostate. 2018 Nov;78(15):1172-1180. doi: 10.1002/pros.23692. Epub 2018 Jul 15.

29.

Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.

Palsgrove DN, Li Y, Pratilas CA, Lin MT, Pallavajjalla A, Gocke C, De Marzo AM, Matoso A, Netto GJ, Epstein JI, Argani P.

Am J Surg Pathol. 2018 Sep;42(9):1166-1181. doi: 10.1097/PAS.0000000000001111.

30.

Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.

Yegnasubramanian S, De Marzo AM, Nelson WG.

Cold Spring Harb Perspect Med. 2019 Apr 1;9(4). pii: a030445. doi: 10.1101/cshperspect.a030445. Review.

PMID:
29959132
31.

Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases.

Alharbi AM, De Marzo AM, Hicks JL, Lotan TL, Epstein JI.

Am J Surg Pathol. 2018 Oct;42(10):1286-1296. doi: 10.1097/PAS.0000000000001112.

PMID:
29944471
32.

Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate.

Markowski MC, Hubbard GK, Hicks JL, Zheng Q, King A, Esopi D, Rege A, Yegnasubramanian S, Bieberich CJ, De Marzo AM.

Prostate. 2018 Sep;78(13):992-1000. doi: 10.1002/pros.23657. Epub 2018 May 30.

PMID:
29851094
33.

Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer.

Kaur HB, Guedes LB, Lu J, Maldonado L, Reitz L, Barber JR, De Marzo AM, Tosoian JJ, Tomlins SA, Schaeffer EM, Joshu CE, Sfanos KS, Lotan TL.

Mod Pathol. 2018 Oct;31(10):1539-1552. doi: 10.1038/s41379-018-0083-x. Epub 2018 May 30.

34.

ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.

Torres A, Alshalalfa M, Davicioni E, Gupta A, Yegnasubramanian S, Wheelan SJ, Epstein JI, De Marzo AM, Lotan TL.

Prostate. 2018 Sep;78(12):896-904. doi: 10.1002/pros.23646. Epub 2018 May 15.

35.

Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer.

Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, Brennen WN, Marchionni L, Halushka MK, Lupold SE.

Sci Rep. 2018 May 8;8(1):7189. doi: 10.1038/s41598-018-25320-z.

36.

MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.

Bhanvadia RR, VanOpstall C, Brechka H, Barashi NS, Gillard M, McAuley EM, Vasquez JM, Paner G, Chan WC, Andrade J, De Marzo AM, Han M, Szmulewitz RZ, Vander Griend DJ.

Clin Cancer Res. 2018 Aug 1;24(15):3668-3680. doi: 10.1158/1078-0432.CCR-17-3673. Epub 2018 May 1.

37.

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.

Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan TL, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, Yegnasubramanian S, Luo J, Mehra R, Antonarakis ES, Drake CG, De Marzo AM.

Am J Pathol. 2018 Jun;188(6):1478-1485. doi: 10.1016/j.ajpath.2018.02.014. Epub 2018 Mar 22.

38.

Clinical implications of PTEN loss in prostate cancer.

Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL.

Nat Rev Urol. 2018 Apr;15(4):222-234. doi: 10.1038/nrurol.2018.9. Epub 2018 Feb 20. Review.

PMID:
29460925
39.

Diagnostic Utility of Cytokeratin-5 for the Identification of Proliferative Inflammatory Atrophy in the Canine Prostate.

Palmieri C, Story M, Lean FZX, Akter SH, Grieco V, De Marzo AM.

J Comp Pathol. 2018 Jan;158:1-5. doi: 10.1016/j.jcpa.2017.10.172. Epub 2017 Dec 1.

PMID:
29422309
40.

Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells.

Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, Mucci LA, Giovannucci EL, Stampfer MJ, Yoon G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA.

Prostate. 2018 Feb;78(3):233-238. doi: 10.1002/pros.23462. Epub 2017 Nov 22.

41.

Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression.

Valkenburg KC, De Marzo AM, Williams BO.

Oncotarget. 2017 May 17;8(46):80265-80277. doi: 10.18632/oncotarget.17919. eCollection 2017 Oct 6.

42.

Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides.

Baena-Del Valle JA, Zheng Q, Hicks JL, Fedor H, Trock BJ, Morrissey C, Corey E, Cornish TC, Sfanos KS, De Marzo AM.

Am J Clin Pathol. 2017 Nov 2;148(5):398-415. doi: 10.1093/ajcp/aqx094.

43.

The inflammatory microenvironment and microbiome in prostate cancer development.

Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM.

Nat Rev Urol. 2018 Jan;15(1):11-24. doi: 10.1038/nrurol.2017.167. Epub 2017 Oct 31. Review.

PMID:
29089606
44.

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations.

Markowski MC, De Marzo AM, Antonarakis ES.

Expert Opin Investig Drugs. 2017 Dec;26(12):1391-1397. doi: 10.1080/13543784.2017.1393518. Epub 2017 Oct 27. Review.

PMID:
29032717
45.

CXXC5 expression in prostate cancer: implications for cancer progression.

Benedetti I, De Marzo AM, Geliebter J, Reyes N.

Int J Exp Pathol. 2017 Aug;98(4):234-243. doi: 10.1111/iep.12241.

46.

MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.

Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ, Meeker AK, Heaphy CM, Graham MK, De Marzo AM.

J Pathol. 2018 Jan;244(1):11-24. doi: 10.1002/path.4980. Epub 2017 Nov 14.

47.

Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.

Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, Zhao P, De Marzo AM, Antonarakis ES, Wang M, Wu X, Luo Y, Su N, Nava Rodrigues D, Figueiredo I, Welti J, Park E, Ma XJ, Coleman I, Morrissey C, Plymate SR, Nelson PS, de Bono JS, Luo J.

Eur Urol. 2018 May;73(5):727-735. doi: 10.1016/j.eururo.2017.08.009. Epub 2017 Sep 1.

48.

Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer.

Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, Yegnasubramanian S, Mangold LA, Partin AW, Sfanos KS.

J Urol. 2018 Jan;199(1):161-171. doi: 10.1016/j.juro.2017.08.001. Epub 2017 Aug 7.

49.

MSH2 Loss in Primary Prostate Cancer.

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL.

Clin Cancer Res. 2017 Nov 15;23(22):6863-6874. doi: 10.1158/1078-0432.CCR-17-0955. Epub 2017 Aug 8.

50.

A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts.

Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman SM, Parnes HL, Thompson IM, Goodman PJ, Tangen CM, De Marzo AM.

Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1549-1557. doi: 10.1158/1055-9965.EPI-17-0503. Epub 2017 Jul 28.

Supplemental Content

Loading ...
Support Center